Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease
Recruiting
- Conditions
- HealthyAlzheimer Disease
- Interventions
- Diagnostic Test: Positron Emission Tomography (PET) using two PET tracer under IND
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 71
- Registration Number
- NCT05582200
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Venous Ethanol for Ventricular Tachycardia
Phase 2
Recruiting
- Conditions
- Ventricular TachycardiaIschemic Cardiomyopathy
- Interventions
- Procedure: Catheter ablationDrug: Venous ethanol
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 156
- Registration Number
- NCT05511246
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Educating Women About Pelvic Floor Disorders During Pregnancy
Not Applicable
Completed
- Conditions
- Pelvic Floor DisordersPelvic Organ ProlapseStress Urinary Incontinence
- Interventions
- Other: Written HandoutsOther: Interactive Workshop
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT05440539
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Survey of Human Rabies Immune Globulin Safety in Children
Recruiting
- Conditions
- PediatricsRabiesRabies HumanRabies Virus Infection
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05382650
- Locations
- 🇺🇸
Houston Methodist, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2
Recruiting
- Conditions
- ER-Positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT05305924
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
Phase 2
- Conditions
- Interstitial FibrosisKidney Transplant; ComplicationsKidney Transplant Failure and RejectionKidney Transplant FailureKidney Transplant RejectionKidney Failure, ChronicGraft Rejection
- Interventions
- Drug: PlaceboDrug: Fingolimod
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05285878
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients
Not Applicable
- Conditions
- PainPain, Postoperative
- Interventions
- Device: cryoSPHERE AblationDrug: Bupivacaine
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 75
- Registration Number
- NCT05276258
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
Phase 2
Recruiting
- Conditions
- Urothelial Carcinoma Bladder
- Interventions
- Drug: SasanlimabRadiation: Stereotactic Body Radiation TherapyProcedure: Radical Cystectomy + pelvic lymph node dissection + urinary diversion
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 33
- Registration Number
- NCT05241340
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Phase 4
Recruiting
- Conditions
- Hepatocellular CarcinomaHepatocellular Cancer
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT05185505
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
Phase 2
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: LenvatinibProcedure: Transcatheter Arterial Chemoembolization
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05171335
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath